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Abstract
Background: Despite the importance of invasive Staphylococcus aureus (ISA) infection, its overall burden in
non-selected populations has only been defined in a small number of studies in Europe and North America. To
define the characteristics of ISA infections in Korea, we conducted a multi-center cohort study to estimate
population-based incidence rates.
Methods: We conducted a multicenter prospective cohort study at nine university-affiliated active-surveillance core
centers (ASCs) in three regions of Korea. To cover all available clinical microbiologic laboratories, we classified the
laboratories in these regions into three groups according to their clinical environment as: 1) Nine ASCs, 2) Five
major commercial laboratories and 3) Forty-four acute-care hospital-affiliated microbiology laboratories. We
requested all the laboratories to report prospectively their numbers of cases of S. aureus isolated from normally
sterile sites. Detailed clinical information was collected about the cases in the nine ASCs.
Results: From 1 July 2009 to 30 June 2011, a total of 1,198 cases of ISA infection were identified at the nine ASCs,
including 748 (62%) methicillin-resistant S. aureus (MRSA) infections. Most (81%) ISA infections were healthcare-
associated (HCA): 653 (55%) hospital-onset and 322 (27%) community-onset. 223 (19%) were community-associated
infections. The most common primary diagnosis was catheter-associated infection (225 cases, 19%). Respiratory tract
infection (160, 13%), skin & soft tissue (152, 13%) and bone & joint infections (120, 10%) were also common. 30-day
and 12-week mortality rates were 25.6% (262/1,024) and 36.5% (314/860), respectively. Complications, including
metastatic infection within 12 weeks, occurred in 17.8% of ISA infections. The most common site of metastatic
infection was the lung (9.8%, 84/860). Based on the total of 2,806 observed cases of ISA infection, estimated annual
rates of ISA and invasive MRSA infections were 43.3 and 27.7 per 100,000 populations, respectively.
Conclusions: Our data provide important information about the clinical characteristics of ISA infections. We
estimate that over 21,000 ISA infections and 13,000 invasive MRSA infections occurred in Korea in 2010.
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Background
Staphylococcus aureus is one of the most important bac-
terial pathogens. It is not only the major cause of skin
and soft tissue infection in the community setting, but
also the second most common pathogen causing severe
nosocomial infections, including bacteremia, pneumonia
and surgical site infections [1]. Invasive S. aureus (ISA)
infection is associated with a high mortality rate, and im-
poses a substantial cost and resource burden on the
healthcare system [2]. There are also growing concerns
about increasing methicillin-resistant S. aureus (MRSA)
infections in both community and nosocomial settings.
Although rates of community-associated (CA) MRSA in-
fection are still low in Korea, MRSA accounts for over 60%
of S. aureus nosocomial isolates, and there has also been a
shift to increasing rates of CA-MRSA disease [3,4].
Despite the importance of ISA infection, its overall
burden in non-selected populations has only been de-
fined in a small number of studies in Europe and North
America [5-10]. Therefore, we conducted a multi-center
prospective cohort study to characterize the clinical
spectrum of ISA infections, identify the risk factors for
mortality and estimate population-based incidence rates.
Methods
Patient population and surveillance
From 1 July 2009 to 30 June 2011, this study was con-
ducted at nine university-affiliated active-surveillance
core centers (ASCs), located in two provinces (Jeollabuk-
do, Jeollanam-do), one metropolitan city (Gwangju), and
one new town (Goyang), which together accounted for
12.1% (5,899,540 / 48,580,293) of the Korean population
in 2010 (Figure 1) [11]. Because of their geographical
proximity, Gwangju and Jeollanam-do were united into
one area, referred to as Gwangju/Jeollanam-do in this
study. To estimate population-based incidence rates, we
classified the laboratories in the surveillance area into
three groups, according to their clinical environment: 1)
nine university-affiliated active-surveillance core centers
(ASCs), 2) five major commercial laboratories and 3)
forty-four acute-care hospital-affiliated microbiology la-
boratories covering all available clinical microbiologic
laboratories.
The nine university-affiliated ASCs (group 1) each had
one or more infectious diseases specialists. Cases of
S. aureus isolated from normally sterile sites were col-
lected prospectively from both the laboratories and the
Figure 1 The three participating Korean regions. Because of geographical proximity, the 2 provinces (Jeollabuk-do, Jeollanam-do),
1 metropolitan city (Gwangju), and 1 new town (Goyang) were classified into 3 regions (in Gray).
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active surveillance core centers by infectious disease
specialists. Detailed clinical information about the cases
in the nine ASCs was also collected by trained research
nurses or infectious diseases specialists using standard-
ized case record forms. All S. aureus isolates from nor-
mally sterile sites in the 9 ASCs were sent to the
coordinating center (Seoul National University Bundang
Hospital), to confirm their microbiologic profiles. We
also collected the number of cases of S. aureus acquired
at normally sterile site from all 5 major commercial la-
boratories, which generally deal with requests from local
clinics that lack clinical microbiologic laboratories (group
2). In the end we identified 44 clinical microbiology la-
boratories qualified by the Korean Association of Quality
Assurance for Clinical Laboratories in the surveillance
area [12]. We also requested the 44 hospitals (group 3) to
report their number of cases of ISA infection. In contrast
to the 9 ASCs (group 1), the clinical microbiologic
laboratories in group 2 and group 3 were requested to
volunteer to participate in this surveillance. In addition,
the number of cases was only passively reported without
residency data, and separate audits to identify ISA cases
were not performed in groups 2 and 3.
This study was approved by the institutional review
board of Seoul National University Bundang Hospital in
compliance with the Helsinki Declaration.
Definitions
A case of ISA infection was defined by the isolation of S.
aureus from a normally sterile site. Normally sterile sites
included blood, cerebrospinal fluid, pleural fluid, pericar-
dial fluid, peritoneal fluid, joint/synovial fluid, bone,
internal body sites (lymph node, brain, heart, liver,
spleen, vitreous fluid, kidney, pancreas, or ovary), and
other normally sterile sites. When repeated cultures
from normally sterile sites were positive in a single pa-
tient within 12 weeks of the onset of illness, the number
of ISA infections was counted as one.
Community-onset infections were those that were ei-
ther present or incubating at the time of hospital admis-
sion, or were found in the first positive culture obtained
within 48 h of admission. Community-onset infections
were classified into healthcare-associated (HCA) and
community-associated (CA). If a patient fulfilled any
of the following criteria, the infection was classified as
HCA [9]: (1) presence of an invasive device at the
time of admission or of onset of infection; (2) history
of MRSA infection or colonization in the previous
6 months; (3) history of surgery, hospitalization, dialysis,
or residence in a long-term care facility in the previous
12 months. ISA infection was classified as CA when it
did not fit the above criteria for HCA infection. A case
was classified as hospital-onset if the first S. aureus
culture was obtained 48 h or more after admission to
the hospital. A primary diagnosis was made on the basis
of the clinical, radiological, and microbiological informa-
tion [13]. Clinical isolates were confirmed as S. aureus,
and were tested for antimicrobial susceptibility by stand-
ard techniques. The antimicrobial therapy was consid-
ered ‘appropriate’ if the treatment regimen included
antibiotics active in vitro, and the dosage and route of
administration were in conformity with current medical
standards. Metastatic infection was defined as the pres-
ence of microbiological or radiographic evidence of S.
aureus infection caused by hematogenous seeding [14].
The initial treatment response was assessed 72 hours
after starting antimicrobial therapy, and ‘failure’ was de-
fined if patients died or when their illness deteriorated
or there was no reduction in fever, leukocytosis or other
signs of infection [15].
Data management and analyses
Differences in proportions were compared by Fisher’s
exact test or the chi-square test, and means were com-
pared by Student’s t-test. To identify the independent
risk factors for 30-day mortality, a stepwise multiple
logistic regression model was used. Risk factors with
P values of less than .10 in univariate analysis were
included in the initial model, and forward stepwise selec-
tion was performed to define significant risk factors.
Charlson’s weighted index of co-morbidity (WIC) and all
underlying diseases were analyzed in a separate logistic
regression model to avoid data overlap in the multivari-
ate analysis. P values of less than .05 were considered
statistically significant in the multivariate analysis. IBM
PASW for Windows (version 20 software package; SPSS
Inc., Chicago, IL, USA) was used for all analyses.
Results
Clinical characteristics of ISA infections
During the 2-year period (1 July 2009 to 30 June 2011),
a total of 1,198 cases of ISA infections, including 748
(62%) MRSA infections, were observed at 9 ASCs.
Median age of patients was 64 years (interquartile range,
IQR: 48 to 74 years), and 733 (61%) patients were male.
Most (81%) ISA infections were HCA infections: 653
(55%) hospital-onset, 322 (27%) community-onset. 223
(19%) were CA infections. Of 1,198 cases, 1,026 (86%)
patients had ≥1 positive blood-culture result, and 38
(3%) had a positive result for pleural fluid. Peritoneal
fluid yielded positive results for 37 patients (3%), CSF
for 26 (2%), synovial fluid for 23 (2%), culture of
deep-tissue samples for 22 (2%) and other sterile sites
for 26 (2%).
Excluding the cases with unknown primary site of
infection, the most common primary diagnosis was
catheter-associated infection (225 cases, 19%). Respira-
tory tract infection, skin & soft tissue and bone & joint
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infections were also common. The clinical spectra and
characteristics of the ISA infections according to site
of infection are listed in Table 1.
Clinical outcomes and risk factors for mortality
The 30-day mortality rate was 25.6% (262/1,024). 12-
week mortality rate was 36.5% (314/860). 455 (52.9%)
patients recovered from ISA infection without recur-
rence or complications, assessed at 12 weeks after onset
of illness. 3.1% (27/860) of the patients with ISA
infections suffered recurrence within 12 weeks, and 16%
(138/860) had metastatic infections. The most common
site of metastatic infection was the lung (9.8%, 84/860).
The clinical outcomes of the ISA infections are listed in
Table 2.
The significant risk factors associated with 30-day mortal-
ity identified by univariate analysis, and the results of
multivariate analysis of risk factors, are presented in Table 3.
In multivariate analysis, extreme age (≥65 or <6 years),
steroid use within 1 month, severe underlying disease
(Charlson’s WIC ≥3), presentation with severe sepsis or
septic shock, presence of metastatic infection of the lung,
and inappropriate empirical antibiotics were significantly
associated with 30-day mortality due to ISA infection. On
the other hand, skin and soft tissue infection decreased the
risk of 30-day mortality. Among the underlying illnesses,
connective tissue disease, moderate to severe liver disease,
and metastatic solid tumor were independently associated
with 30-day mortality.
Estimating incidence rates
In addition to the 1,198 cases of ISA infection that were
identified by the 9 ASCs, 724 were reported from the
5 major commercial laboratories. Of the total of 44 hos-
pitals with clinical microbiology laboratories, 10 (23%)
volunteered to respond to our approach, and reported
884 cases of ISA infections. Thus during the 2-year
period, a total of 2,806 cases of ISA infection were re-
corded by surveillance, including 1,820 (64.9%) MRSA
infections. Median numbers of beds in the participating
10 hospitals and 34 non-participating ones were 257
(interquartile range, IQR: 201-493) and 235 (IQR:
193-294), respectively (P = 0.303 by t-test). After adjust-
ing by the number of total beds in the 44 hospitals, we
estimated the number of ISA infections in those hospi-
tals to be 3,170.
The crude annual rates of ISA and invasive MRSA in-
fections in the 3 regions of Korea in 2010 were esti-
mated to be 43.3 and 27.7 per 100,000 populations,
respectively. Estimated incidences of ISA infection, S.
aureus bacteremia, invasive MRSA infection and MRSA
bacteremia by surveillance site are listed in Table 4.
Discussion
In the present study we described the clinical character-
istics of ISA infection in Korea based on multicenter co-
hort data. Excluding the cases of unknown primary site
of infection, the most common primary diagnosis was
catheter-associated infection (225 cases, 19%), followed
by pneumonia and skin and soft tissue infection. Because
we gathered the detailed clinical information from only
9 ASCs (group 1), which were mostly tertiary-care
and/or university-affiliated hospitals, our data has a ten-
dency to over-represent healthcare-associated settings.
In fact, 975 (81%) cases were healthcare-associated.
Hence, we cannot extrapolate the observed clinical char-
acteristics to all community-based institutions. However,
Table 1 Clinical characteristics of 1,198 patients with invasive Staphylococcus aureus infections in 9 active surveillance

















Catheter-associated 225 (19) 169 (75) 63 (49-63) 0 57 (25) 168 (75) 52/201 (26)
Respiratory tract 160 (13) 109 (68) 70 (55-77) 34 (21) 32 (20) 94 (59) 52/132 (39)
Skin and soft tissue 152 (13) 71 (47) 65 (51-74) 40 (26) 50 (33) 62 (41) 23/128 (18)
Surgical site 103 (9) 87 (85) 61 (45-70) 6 (6) 17 (17) 80 (78) 13/99 (13)
Bone and joint 120 (10) 57 (48) 67 (54-73) 51 (43) 37 (31) 32 (27) 14/107 (13)
Endocarditis 23 (2) 7 (30) 64 (45-72) 9 (39) 13 (57) 1 (4) 7/18 (39)
Intra-abdominal 84 (7) 62 (74) 64 (45-74) 12 (14) 30 (36) 42 (50) 21/76 (28)
Urinary tract 22 (2) 13 (59) 69 (56-76) 5 (23) 7 (32) 10 (46) 6/17 (35)
Others 4 (0) 4 (100) 50 (39-60) 1 (25) 1 (25) 2 (50) 0/3 (0)
Unknown 305 (26) 169 (55) 62 (38-74) 65 (21) 78 (26) 162 (53) 74/243 (30)
Total 1,198 748 (62) 64 (48-74) 223 (19) 322 (27) 653 (55) 262/1,024 (26)
Data indicate no. (%) of patients. MRSA, methicillin-resistant S. aureus; IQR, interquartile range.
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considering that there are few epidemiologic data for
Korea, we believe that our findings on the clinical spec-
tra should provide valuable information about ISA
infection.
We followed up 72% (860/1,198) of the patients for
12 weeks to evaluate recurrence and complications, as
well as mortality. 12 week mortality was quite high
(36.5%) and survival without recurrence or complica-
tions was only 52.9%. Complications including meta-
static infection occurred in 17.8% of the ISA infections,
similar to previous reports [1,16]. However, subsequent
endocarditis occurred in only 2.3% of our patients.
Considering that 86% of the patients had ≥1 positive blood-
culture result, endocarditis was quite rare compared to
previous studies of S. aureus bacteremia [17-19]. However,
we should take into account that echocardiography was
performed in only 319 (37%) patients, and transesophageal
echocardiography in only 20 (2.3%) patients. Therefore, to
evaluate accurately the prevalence of endocarditis after ISA
infection, further studies are needed using universal or se-
lected screening echocardiography, especially in S. aureus
bacteremic patients.
A number of conditions were identified as risk factors
for 30-day mortality in patients with ISA infection in the
nine ASCs (Table 4). As in previous studies of S. aureus
bacteremia, older age, use of immunosuppressants,
severe underlying disease, high severity of illness, and in-
appropriate definitive antibiotics were independent risk
factors for mortality [8,20-22]. In contrast to other stud-
ies, respiratory tract infection itself did not increase the
risk of death, whereas metastatic infection of the lung
was an independent risk factor [21,22]. However, be-
cause there was a possibility of misclassification between
the primary focus and metastatic infection site, the clin-
ical impact of this finding is unclear. Meanwhile, a num-
ber of studies have suggested that methicillin resistance
is a risk factor for mortality in patients with S. aureus in-
fection [23,24]. However, in our study, MRSA infection
was not associated with increased risk of 30-day mortal-
ity in multivariate analysis.
In the present study we tried to estimate incidence
rates of ISA infection in Korea for the first time. Based
on the 2,806 observed cases of ISA infection, we
estimated that over 21,000 ISA infections and 13,000
invasive MRSA infections occurred in Korea in 2010.
Our estimated incidences of ISA and invasive MRSA
infection (43.3 and 27.7 per 100,000 populations) are
higher than those in Calgary, Canada and comparable to
those in the United States [8,9,20]. Recently, Laupland
et al. reported that the overall contemporary incidence
of S. aureus bloodstream infection (SA-BSI) has aver-
aged 26.1 per 100,000 in 9 regions of 5 countries;
Finland, Australia, Sweden, Canada and Denmark [25].
Population-based studies conducted in many regions
around the world have identified SA-BSI incidence rates
of 15–40 per 100,000 population per year [6,8,20,26-28].
Our estimate (S. aureus bacteremia: 34.4 per 100,000,
interval 15.2-46.7) was thus similar to, or somewhat
higher than, that of other countries.
Patients who live outside a given population area fre-
quently have characteristics that are different from those
of the endogenous population, and failure to exclude
these cases will result in an overestimate of disease
occurrence as well as introduce a ‘referral bias’ [29].
Among the total of 1,510 ISA infections, we excluded
312 (20.7%) patients who were not resident in the stud-
ied population of the 9 ASCs (group 1). However, we did
not investigate where the patient in group 2 and group 3
resided. However, considering that the ISA cases in
groups 2 and 3 came from community-based clinics and
hospitals with acute presentation and severe ISA infec-
tions, we believe that the effect of imported cases was
minimal. On the other hand, we may actually have
underestimated the incidence of invasive MRSA disease
if persons in the surveillance areas sought health care
from facilities using laboratories outside that area. In
our data, the incidence (19.9 per 100,000) of ISA infec-
tion in Goyang was only one-third of that (56.7) in
Table 2 Clinical outcomes of invasive Staphylococcus
aureus infections in 9 active surveillance core centers in 3
regions of Korea, July 2009 ~ June 2011
Patients with No. of
cases (%)
Treatment failure assessed at 72 hours after onset
of illness
225 /991 (22.7)
30-day mortality 262 /1,024 (25.6)
Clinical outcomes assessed at 12-week after onset
of illness
Total No. = 860
Recurrence 27 (3.1)
Complications 153 (17.8)







Survival without recurrence or complications 455 (52.9)
12-week mortality 314 (36.5)
Data indicate no. (%) of patients.
a15 patients were diagnosed with 2 or more sites of metastatic infection.
bEchocardiography was performed in 319 patients.
cBone scan and/or MRI was performed in 82 patients.
dOphthalmologic examination was performed in 53 patients.
eOthers: these are central nervous system (4 patients), intra-abdominal (6),
joint space (6), myositis (2), pericardial (1), and endovascular (1) infections.
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Gwangju/Jeollanam-do. This difference may have been
due to the proximity of Goyang to the Seoul metropolitan
area (Figure 1). According to “Medical service usage sta-
tistics per region in 2010” produced by the National
Health Insurance Corporation, the rates of internal use
of medical treatment facilities (medical treatment facil-
ities in the registered region divided by the total facil-
ities) were 88.4% in Jeollabuk-do and 82.2% in Gwangju/
Jeollanam-do, but only 56.1% in Goyang (cf. 90.4% in
Seoul) [30]. Thus, we think that the actual incidence of
ISA infections in the 3 regions was higher than our
estimate.
The measured incidence of invasive infection is
dependent on the number of diagnostic tests performed.
Unfortunately, we did not collect data on how many
blood cultures and invasive diagnostic samples were
tested at each hospital. However, Kim et al. recently re-
ported the number of blood cultures examined per 1,000
Table 3 Significant risk factors associated with 30-day mortality in 1,024 patients with invasive Staphylococcus aureus
infections in 9 active surveillance core centers in 3 regions of Korea, July 2009 ~ June 2011








Age, ≥65 or <6 years 370 (49) 181 (69) 2.367 (1.757-3.189) 2.068 (1.822-3.575)
Steroid use within 1 month 67 (9) 40 (15) 1.869 (1.228-2.844) 1.891 (1.150-3.107)
Indwelling medical device 287/741 (39) 112/248 (45) 1.303 (0.974-1.742) NS
Long-term care facility resident 288/703 (41) 117/240 (49) 1.371 (1.021-1.840) NS
Underlying illness
Charlson’s WIC, ≥3 235 (31) 130 (50) 2.209 (1.658-2.942) 1.796 (1.294-2.495)
Chronic pulmonary disease 26 (3) 23 (9) 2.724 (1.526-4.864) NS
Connective tissue disease 20 (3) 14 (5) 2.094 (1.042-4.209) 3.042 (1.342-6.895)
Ulcer disease 71 (9) 41 (16) 1.806 (1.194-2.729) NS
Moderate to severe liver disease 36 (5) 30 (12) 2.608 (1.571-4.328) 4.004 (2.205-7.273)
Metastatic solid tumor 31 (4) 38 (15) 4.000 (2.433-6.578) 3.724 (2.106-6.584)
Primary diagnosis, infection
Respiratory tract 80 (10) 52 (39) 2.111 (1.441-3.093) NS
Skin and soft tissue 105 (14) 23 (9) 0.602 (0.375-0.968) 0.598 (0.340-0.998)
Surgical site 86 (11) 13 (5) 0.410 (0.225-0.749) NS
Bone and joint 93 (12) 14 (5) 0.406 (0.227-0.726) NS
Unknown 169 (22) 74 (28) 1.381 (1.004-1.900) NS
MRSA infection 467 (61) 181 (69) 1.412 (1.046-1.905) NS
Severe sepsis or septic shock 65 (9) 88 (34) 5.423 (3.780-7.781) 6.173 (4.107-9.277)
Metastatic infection of lung 46 (6) 27 (10) 1.788 (1.087-2.941) 2.169 (1.223-3.847)
Inappropriate empirical antibiotics 323 (42) 129 (49) 1.318 (0.995-1.747) NS
Inappropriate definitive antibiotics 85 /756 (11) 35 /214 (17) 1.650 (1.084-2.512) 3.199 (2.352-4.350)
Data indicate no. (%) of patients. Total no. of cases was 1,024, because detailed clinical information was not available for 174 patients. Charlson’s weighted index
of co-morbidity and each underlying diseases were analyzed in separate logistic regression models to avoid data overlap in the multivariate analysis.
OR, odds ratio; CI, confidence interval; MRSA, methicillin-resistant S. aureus; Charlson’s WIC, Charlson’s weighted index of co-morbidity; NS, not significant.
aRisk factors with P values of less than .10 in univariate analysis were included in the initial model. P values of less than .05 were considered statistically significant
in the multivariate analysis.
Table 4 Estimated incidence of invasive Staphylococcus aureus infection in 3 regions of Korea, July 2009 ~ June 2011













Goyang 180 8.9 15.2 11.2 19.9 905,076
Jeollabuk-do 552 15.2 21.7 21.8 31.0 1,777,220
Gwangju/Jeollanam-do 1,824 29.2 46.7 35.6 56.7 3,217,244
Total 2,555 21.9 34.4 27.7 43.3 5,899,540
MRSA, methicillin-resistant S. aureus.
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patient days at seven Korean university-affiliated hospi-
tals in 2010 [31]. Because the characteristics of the 7
participating university-affiliated hospitals were similar
to those of our 9 ASCs, we could assume that our num-
ber of blood cultures was similar. The mean number of
blood cultures per 1,000 days was 110 ±23 (SD), range
65 to 129 [31], which is similar to or somewhat lower
than the number (103-188) of blood cultures per 1,000
patient days suggested by Cumitec 1C [32]. The differ-
ence might be secondary to a difference in the propor-
tion of patients with acute illnesses or to different blood
culture ordering systems. Most hospitals (about 70%) in
Korea examine two blood cultures per adult patient and
one culture per child patient (about 80%) rather than
three sets.
Although we tried to evaluate all cases of ISA infection
in the three Korean regions, we were unable to collect
ISA cases from a large number (34) of the 44 hospitals
in group 3. While there was no significant difference in
number of beds between the 10 participating hospitals
and other 34 hospitals, our group 3 data could be biased
because we depended on voluntary reporting of numbers
of ISA infections by these hospitals (i.e. volunteer bias).
Nevertheless, because these were community-based hos-
pitals whose patients have similar clinical characteristics,
we were obliged to estimate the rate of ISA infection in
the 44 hospitals from the cases in the 10 hospitals that
responded to our approach, based on the difference in
number of beds. When we calculated the incidence from
the exact number of cases observed, the crude annual
rates of ISA and invasive MRSA infections were reduced
to 23.8 (18.9 ~ 27.8) and 15.4 (11.2 ~ 17.8) per 100,000
populations, respectively.
Conclusions
In conclusion, this is the first large-scale prospective cohort
study to evaluate the clinical characteristics of patients with
ISA infections and the risk factors for mortality, together
with an attempt to estimate population-based incidence
rates. We have estimated that over 21,000 ISA infections
and 13,000 invasive MRSA infections occurred in Korea in
2010. We believe that further studies based on well-
documented, non-selected populations are warranted in
order to establish healthcare and research priorities and
evaluate the effectiveness of preventative interventions.
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